XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Operating Segments and Related Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Operating Segments and Related Information
17. Operating Segments and Related Information

The Company currently has one primary reportable geographic segment - United States, and primarily all revenue is derived in the United States, and primarily all PP&E and intangible assets reside in the United States. The reportable segments are identified based on the nature of the services and products provided, the organizational structure, and the internal reporting system used by the Chief Operating Decision Maker ("CODM") to assess performance and allocate resources. The Company has three reportable operating segments, plus the Other segment, based on management’s organization of the enterprise - Infrastructure, Life Sciences, Spectrum, and Other. The Company also has a Non-Operating Corporate segment. All inter-segment transactions are eliminated on consolidation. There are no inter-segment revenues. Refer to Note 1. Organization and Business for additional information on the organizational structure of the business and Note 3. Revenue and Contracts in Process for additional information on revenue by segment.

The Chief Operating Decision Maker ("CODM") for the Company is the Interim CEO, Paul Voigt. The CODM is primarily responsible for allocating resources at all levels that do not require board approval. The CODM monitors the performance of each segment and is responsible for making strategic decisions regarding capital and resource allocation. The CODM uses a combination of monthly reports, which detail revenue and income (loss) from operations, and quarterly summaries, which include detailed breakdowns of each segment's income (loss) from operations, to evaluate segment performance, allocate resources and make strategic decisions. These financial metrics are used to view operating trends, perform analytical comparisons and benchmark performance between periods and to monitor budget-to-actual variances on a monthly basis. The primary U.S. GAAP metric used by the CODM in assessing segment performance is income (loss) from operations.

Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):
Three Months Ended March 31, 2025
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Revenue$264.9 $3.1 $6.2 $— $274.2 
Cost of revenue223.5 2.3 2.9 — — 228.7 
Selling, general and administrative expenses
29.3 3.7 1.9 2.9 — 37.8 
Depreciation and amortization3.1 0.1 1.2 — — 4.4 
Other operating income
(0.1)— — — — (0.1)
Income (loss) from operations$9.1 $(3.0)$0.2 $(2.9)$— $3.4 
Other data:
Capital expenditures (1)
$4.1 $0.1 $0.5 $— $— $4.7 
Investments (2)
$— $1.8 $— $2.3 $— $4.1 
Total assets
$671.9 $11.7 $178.3 $6.1 $— $868.0 
(1) Capital expenditures reflect cash expenditures for the three months ended March 31, 2025.
(2) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of March 31, 2025.
Three Months Ended March 31, 2024
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Revenue$307.9 $1.0 $6.3 $— $— $315.2 
Cost of revenue263.1 0.6 2.9 — — 266.6 
Selling, general and administrative expenses30.9 3.5 1.9 3.2 — 39.5 
Depreciation and amortization3.0 0.1 1.3 — — 4.4 
Other operating loss (1)
1.6 — — 0.3 — 1.9 
Income (loss) from operations
$9.3 $(3.2)$0.2 $(3.5)$— $2.8 
Other data:
Capital expenditures (2)
$5.2 $0.1 $0.3 $— $— $5.6 
December 31, 2024
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Investments (3)
$— $1.8 $— $1.8 $— $3.6 
Total assets
$683.6 $11.9 $178.9 $16.7 $— $891.1 
(1) Other operating loss for the three months ended March 31, 2024, primarily consisted of a loss on disposal related to a plant closure at our Infrastructure segment.
(2) Capital expenditures reflect cash expenditures for the three months ended March 31, 2024.
(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2024.
 Three Months Ended March 31,
20252024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations$3.4 $2.8 
Interest expense(20.2)(17.2)
Loss from equity investees(5.9)(1.2)
Other income (expense), net4.0 (1.2)
Loss from operations before income taxes$(18.7)$(16.8)